You can Subscribe to our RSS FEED: which delivers brain tumor news and additions to the website via RSS.
Click HERE for details on RSS.
Displaying items 1 to 25 of about 5928
Next 25
09/15/2025
Reminder - Webinar Thursday!
Journal of Neuro-Oncology Publishes New Data Reinforcing GammaTile® Efficacy in Treating Recurrent Brain Metastases
09/09/2025
Upcoming webinar!
Dr. Steven Brem joins the Musella Foundation as Chief Scientific Advisor!
09/08/2025
The 6th Annual Mark Salkowski 5k Run/Walk
Carmustine Wafers (Gliadel) in Brain Metastases: Revisiting an Old Concept with New Insights
PNOC Foundation Launches $50 Million "Lose No Child" Campaign to Transform the Future of Treatment for Kids with Brain Cancer
5th Gliomatosis Cerebri Conference
08/26/2025
Reminder: Webinar Tomorrow!
08/18/2025
Plus Therapeutics Presents Positive ReSPECT-LM Clinical Trial Results of REYOBIQ™ in Leptomeningeal Metastases
Phase 1/2a study on Lisavanbulin Published in Journal Cell Reports Medicine
Social Security makes a big change to eligibility rules
08/11/2025
March On for Brain Injury - Long Island Walk
08/10/2025
Dual Immune Check Point Blockade in MGMT-Unmethylated Newly Diagnosed Glioblastoma: NRG Oncology BN007, a Randomized Phase II/III Clinical Trial
08/06/2025
Jazz Pharmaceuticals Announces U.S. FDA Approval of Modeyso™ (dordaviprone) as the First and Only Treatment for Recurrent H3 K27M-mutant Diffuse Midline Glioma
Musella Foundation Copay Program now closed to new and renewal applicants
08/04/2025
Bevacizumab alternating chemotherapy for improving the survival of patients with recurrent high-grade glioma
Dana-Farber Research Shows Promise for Targeted Therapies for Pediatric Gliomas
Musella Foundation Copay Program Almost Closed
07/21/2025
Collaboration in US and Global Fight Against Cancer
BCSSA Nurse Navigator featured on Rare Enough Podcast
07/14/2025
4th Annual Tumor Takedown Event
Weill Cornell Medicine Research Team Awarded Grant to Advance Promising Brain Cancer Therapy Using Focused Ultrasound and ThermoDox®
A New Adjuvant Treatment for Glioblastoma Using Aprepitant, Vortioxetine, Roflumilast and Olanzapine: The AVRO Regimen